Anti-hypertensive treatment with magnesium-aspartate-dichloride and its influence on peripheral serotonin metabolism in man: a subacute study.
Dichlormagnesium-aspartate-hydrochloride was given to 12 patients with mild hypertension in antihypertensive indication at a dose of 10.5 mmol Mg2+/day for 3 months. Blood pressure normalized (from 161.7 +/- 3.4/95.8 +/- 0.8 mmHg to 140.4 +/- 4.0/81.7 +/- 0.9 mmHg, after the third month (p < 0.01). While no changes in Mg2+ concentration in serum were observed in patients with normomagnesaemia, in hypomagnesaemic patients vS-Mg level normalized. Renal excretion of Mg2+ increased: from 3.41 +/- 0.36 before to 5.7 +/- 0.57 mmol Mg2+/24 h after treatment, p < 0.01. Mean plasma serotonin (5HT) concentration showed no changes, although a trend towards an increase in platelet 5HT content was observed. Elevated pre-treatment plasma 5-hydroxyindole acetic acid (5HIAA) concentrations normalized (from 137.29 +/- 20.3 to 78.96 +/- 31.64 nmol/l after the third month, p < 0.05). These findings point to a platelet-stabilizing effect of Mg2+. Fractional excretion of 5HIAA increased (from 1.42 +/- 0.27 to 5.4 +/- 1.22 after treatment, p < 0.01) while mean urinary 5HIAA excretion remained unchanged. It is deduced that a) total body 5HT and 5HIAA production was not affected; b) a long-term supplementation of Mg2+ stimulates the transport of 5HIAA in proximal tubules and, probably, intrarenal 5HIAA synthesis. A functional block in 5HT metabolism under Mg2+ treatment is anticipated. Thus, Mg2+ supplementation has renal and extrarenal effects that are important in treating hypertension and its complications.
Sebeková
K
K
Institute of Preventive and Clinical Medicine, Centre of Clinical Pharmacology, Bratislava, Slovak Republic.
Revúsová
V
V
Polakovicová
D
D
Drahosová
J
J
Zverková
D
D
Dzúrik
R
R
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008274:Magnesium / Q000097:blood; D017616:Magnesium Compounds / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012701:Serotonin / Q000097:blood*
D000959:Antihypertensive Agents; D004338:Drug Combinations; D017616:Magnesium Compounds; D001224:Aspartic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008274:Magnesium